Celebrating 25 Years of Richmond Pharmacology

For 25 years, Richmond Pharmacology has been helping sponsors translate scientific discovery into early phase clinical research.

Founded in 2001, Richmond has grown from a single clinical research unit into an internationally recognised early phase clinical research organisation. Today, we support studies across more than 20 therapeutic areas and have contributed to landmark programmes, including the world's first systemically delivered CRISPR-Cas9 therapy.

‍

As we celebrate this milestone, we are reflecting on the people, partnerships and scientific progress that have shaped our journey over the past quarter of a century.

‍

Richmond at 25

• Founded in 2001.

• Supporting research across more than 20 therapeutic areas.

• Contributed to the world's first systemically delivered CRISPR-Cas9 therapy.

• Trusted by sponsors, participants and healthcare partners to deliver complex early phase clinical research.

‍

A Message from Professor Jörg Taubel

To mark Richmond's 25th anniversary, Executive Chairman Professor Jörg Taubel reflects on the company's journey, the principles that have guided it since its founding and the opportunities that lie ahead.

‍

"Over 500 early-phase studies later, what excites me most is how much more there is still to do. The science entering early phase research is becoming more ambitious and complex, bringing new possibilities for patients and new responsibilities for all of us involved in translating those discoveries into clinical research."

‍

Richmond Through the Years

Watch our anniversary film, showcasing the people, milestones and partnerships that have shaped Richmond over the past 25 years.

‍

‍

‍

‍

‍

Explore Our Journey

Our timeline highlights some of the defining moments in Richmond's history, from our founding in 2001 to supporting landmark studies that continue to shape the future of medicine.

‍

Looking Ahead

Science continues to evolve, bringing new opportunities to patients around the world. Richmond remains committed to helping sponsors bring the next generation of medicines safely into early phase clinical research, guided by the same principles of scientific excellence, integrity and participant safety that have defined the organisation for the past 25 years.

‍

‍

‍